Aprizo 10 Tablet

About Aprizo 10 Tablet

Made by Nuvista Pharma Ltd, Aprizo 10 is a tablet whose active ingredient is Apremilast. Aprizo 10 is used for adults with active psoriatic arthritis, a condition where joints become painful and swollen alongside skin problems.

There are 5 brands of Apremilast listed in Bangladesh.

What is Aprizo 10 Tablet?

The tablet Aprizo 10 contains Apremilast and is made by Nuvista Pharma Ltd. Doctors prescribe it for adults with active psoriatic arthritis and for adults with moderate to severe plaque psoriasis who are suitable for phototherapy or systemic therapy. Because it is used for long-term conditions, regular follow-up with your doctor matters. The doctor decides the dose and course.

Uses of Aprizo 10

Aprizo 10 is used for adults with active psoriatic arthritis, a condition where joints become painful and swollen alongside skin problems. It is also used for adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. It is not a painkiller and does not give quick relief; it is a longer-term treatment for these inflammatory conditions. Ask your doctor if you are unsure what it is being prescribed for.

How to use Aprizo 10

Aprizo 10 can be taken with or without food. Aprizo 10 is taken by mouth. Swallow the tablet with water. Do not change the amount or stop on your own, even if you feel better. The doctor decides the dose, the starting schedule and how long you take it; do not change these yourself.

Side effects of Aprizo 10

Less frequent ones include vomiting, upper respiratory tract infection, sore throat, abdominal pain, indigestion, reflux, fatigue, reduced appetite, cough, rash, insomnia and hypersensitivity. The most common side effects are nausea, diarrhoea and headache. Some people notice mood changes or weight loss. Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.

Safety and precautions

Apremilast is pregnancy category C, and it is not known whether it passes into human breast milk, so caution is advised in nursing women. Weight loss has also been reported. Apremilast is pregnancy category C, and it is not known whether it passes into human breast milk, so tell your doctor if you are pregnant, planning pregnancy or breastfeeding. Keep out of reach of children.

Frequently asked questions

What is Aprizo 10 used for?

Aprizo 10 is used for adults with active psoriatic arthritis, a condition where joints become painful and swollen alongside skin problems. It is also used for adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

How is Aprizo 10 used?

Aprizo 10 can be taken with or without food. Aprizo 10 is taken by mouth.

What should I watch for while using Aprizo 10?

Less frequent ones include vomiting, upper respiratory tract infection, sore throat, abdominal pain, indigestion, reflux, fatigue, reduced appetite, cough, rash, insomnia and hypersensitivity. The most common side effects are nausea, diarrhoea and headache.

Who should be careful with Aprizo 10?

Apremilast is pregnancy category C, and it is not known whether it passes into human breast milk, so caution is advised in nursing women. Weight loss has also been reported.

Indications

Apremilast is indicated for the treatment of adult patients with active psoriatic arthritis and moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Pharmacology

Apremilast is a novel, orally available small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4). PDE-4 is a cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase that is predominantly located in inflammatory cells. By inhibiting PDE-4, apremilast increases intracellular levels of cAMP and thereby inhibits the production of multiple proinflammatory mediators including PDE-4, TNF-alpha, interleukin-2 (IL-2), interferon-gamma, leukotrienes, and nitric oxide synthase. By targeting a central component of the inflammatory signaling cascade rather than a single inflammatory marker, PDE-4 inhibition may restore the homeostatic balance between pro- and anti-inflammatory signalling.

Dosage & Administration

The recommended initial dosage titration of Apremilast from Day 1 to Day 5 is shown below. Following the 5-day titration, the recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6. This titration is intended to reduce the gastrointestinal symptoms associated with initial therapy. Apremilast can be administered without regard to meals.

Day 1: 10 mg in morning
Day 2: 10 mg in morning and 10 mg in evening
Day 3: 10 mg in morning and 20 mg in evening
Day 4: 20 mg in morning and 20 mg in evening
Day 5: 20 mg in morning and 30 mg in evening
Day 6: 30 mg twice daily

Dosage adjustment in patients with severe renal impairment. Apremilast dosage should be reduced to 30 mg once daily in patients with severe renal impairment. For initial dosage titration, it is recommended that Apremilast be titrated using only the morning schedule and the evening doses be skipped.

Interaction

Co-administration of strong cytochrome P450 enzyme inducer Rifampin resulted in a reduction of systemic exposure of Apremilast.Therefore.the use of cytochrome P450 enzyme inducers (e.g. Rifampin, Phenobarbital,Carbamazepine, Phenytoin) with Apremilast is not recommended.

Contraindications

Apremilast is contraindicated in patients with a known hypersensitivity to Apremilast or to any of the excipients in the formulation.

Side Effects

The most frequently occurring side effects of Apremilast are nausea, diarrhea and headache. Other less frequent side effects are upper respiratory tract infection, vomiting, naospharyngitis, abdominal pain, hypersensitivity, gastroesophageal reflux disease, dyspepsia, fatigue, decrease appetite, cough, rash, insomnia.

Pregnancy & Lactation

Pregnancy Category C. It is not known whether Apremilast or its metabolites are present in human milk; however, Apremilast was detected in milk of lactating mice. Caution should be exercised when Apremilast is administered to a nursing woman.

Precautions & Warnings

Treatment with Apremilast is associated with an increase in adverse reactions of depression. Patients, their caregivers and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Apremilast if such events occur.

During the controlled period of the studies in psoriatic arthritis, weight decrease between 5-10% of body weight was reported in 10% of subjects treated with Apremilast 30 mg twice daily compared to 3.3% treated with placebo.

Storage Conditions

Store at cool & dry place, protected from light & moisture. Keep the medicine out of the reach of children.

Alternative brands of Apremilast

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.